Redx Pharma PLC in a great place to move forward after Astra deal says CEO

Lisa Anson, chief executive of Redx Pharma PLC (LON:REDX) says the out-license deal with AstraZeneca for its fibrosis porcupine inhibitor is good news for the company and also for people suffering from the condition. Using a porcupine inhibitor in lung-scarring diseases such as IPF is a novel approach, she says, and Astra will take on the drug through all its development and clinical work from here on. Redx has another fibrosis treatment under development that uses a different methodology, so that means two different ways of coming at what is a very nasty condition, she adds. Astra is paying US$17mln upfront for an exclusive licence with up to US$360mln in milestone payments and single-digit royalty payments on sales also part of the deal.